Tags

Type your tag names separated by a space and hit enter

Added Benefit of Immature Oocyte Maturation for Fertility Preservation in Women with Malignancy.
Reprod Sci. 2020 Jul 02 [Online ahead of print]RS

Abstract

To assess the added value of maturing immature oocytes collected during fertility preservation treatments in women with malignancy. A retrospective case-control study analyzing the results of 327 cancer patients undergoing fertility preservation treatments. Oocyte maturation rates and cycle parameters were compared between 3 types of fertility preservation treatments: (1) stimulated IVF cycle (n = 143), (2) non-stimulated IVM cycle (n = 158), (3) follicle aspiration and oocyte collection from ovarian tissue prepared for ovarian tissue cryopreservation followed by in vitro maturation of the immature oocytes (n = 48). The primary outcome measure was the maturation rate and the number of mature oocytes. The secondary outcomes were oocyte fertilization and embryo development rates. The mean maturation rate in IVF cycles was 38% and in the non-stimulated IVM cycles was 55%. In women who chose to cryopreserve their embryos, similar fertilization and embryo cleavage rates were found in oocytes that matured after stimulated IVF cycles compared to non-stimulated IVM cycles. Gonadotropin-releasing hormone agonist triggering, treatment with aromatase inhibitor, or oral contraceptives use before the cycle did not affect the maturation rate. Ovarian stimulation yields the highest number of oocytes or embryos for cryopreservation. Although the maturation rate of immature oocytes collected in stimulated IVF cycles is low, it is still a viable source of oocytes that can be used to improve the efficacy of fertility preservation treatments by increasing the number of mature oocytes available for freezing or fertilization.

Authors+Show Affiliations

Department of Obstetrics and Gynecology, Division of Reproductive Endocrinology and Infertility, McGill University Health Care Centre, 888 Boul de Maisonneuve E #200, Montreal, QC, H2L 4S8, Canada. yonni.co@gmail.com.Department of Obstetrics and Gynecology, Division of Reproductive Endocrinology and Infertility, McGill University Health Care Centre, 888 Boul de Maisonneuve E #200, Montreal, QC, H2L 4S8, Canada.Department of Obstetrics and Gynecology, Division of Reproductive Endocrinology and Infertility, McGill University Health Care Centre, 888 Boul de Maisonneuve E #200, Montreal, QC, H2L 4S8, Canada.Department of Obstetrics and Gynecology, Division of Reproductive Endocrinology and Infertility, McGill University Health Care Centre, 888 Boul de Maisonneuve E #200, Montreal, QC, H2L 4S8, Canada.Department of Obstetrics and Gynecology, Division of Reproductive Endocrinology and Infertility, McGill University Health Care Centre, 888 Boul de Maisonneuve E #200, Montreal, QC, H2L 4S8, Canada.Department of Obstetrics and Gynecology, Division of Reproductive Endocrinology and Infertility, McGill University Health Care Centre, 888 Boul de Maisonneuve E #200, Montreal, QC, H2L 4S8, Canada.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

32617879

Citation

Cohen, Yoni, et al. "Added Benefit of Immature Oocyte Maturation for Fertility Preservation in Women With Malignancy." Reproductive Sciences (Thousand Oaks, Calif.), 2020.
Cohen Y, Tannus S, Volodarsky-Perel A, et al. Added Benefit of Immature Oocyte Maturation for Fertility Preservation in Women with Malignancy. Reprod Sci. 2020.
Cohen, Y., Tannus, S., Volodarsky-Perel, A., Son, W. Y., Tulandi, T., & Buckett, W. (2020). Added Benefit of Immature Oocyte Maturation for Fertility Preservation in Women with Malignancy. Reproductive Sciences (Thousand Oaks, Calif.). https://doi.org/10.1007/s43032-020-00245-z
Cohen Y, et al. Added Benefit of Immature Oocyte Maturation for Fertility Preservation in Women With Malignancy. Reprod Sci. 2020 Jul 2; PubMed PMID: 32617879.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Added Benefit of Immature Oocyte Maturation for Fertility Preservation in Women with Malignancy. AU - Cohen,Yoni, AU - Tannus,Samer, AU - Volodarsky-Perel,Alexander, AU - Son,Weon-Young, AU - Tulandi,Togas, AU - Buckett,William, Y1 - 2020/07/02/ PY - 2020/03/29/received PY - 2020/06/22/accepted PY - 2020/06/02/revised PY - 2020/7/4/entrez KW - Fertility preservation KW - In vitro maturation KW - Ovarian tissue cryopreservation KW - Vitrification JF - Reproductive sciences (Thousand Oaks, Calif.) JO - Reprod Sci N2 - To assess the added value of maturing immature oocytes collected during fertility preservation treatments in women with malignancy. A retrospective case-control study analyzing the results of 327 cancer patients undergoing fertility preservation treatments. Oocyte maturation rates and cycle parameters were compared between 3 types of fertility preservation treatments: (1) stimulated IVF cycle (n = 143), (2) non-stimulated IVM cycle (n = 158), (3) follicle aspiration and oocyte collection from ovarian tissue prepared for ovarian tissue cryopreservation followed by in vitro maturation of the immature oocytes (n = 48). The primary outcome measure was the maturation rate and the number of mature oocytes. The secondary outcomes were oocyte fertilization and embryo development rates. The mean maturation rate in IVF cycles was 38% and in the non-stimulated IVM cycles was 55%. In women who chose to cryopreserve their embryos, similar fertilization and embryo cleavage rates were found in oocytes that matured after stimulated IVF cycles compared to non-stimulated IVM cycles. Gonadotropin-releasing hormone agonist triggering, treatment with aromatase inhibitor, or oral contraceptives use before the cycle did not affect the maturation rate. Ovarian stimulation yields the highest number of oocytes or embryos for cryopreservation. Although the maturation rate of immature oocytes collected in stimulated IVF cycles is low, it is still a viable source of oocytes that can be used to improve the efficacy of fertility preservation treatments by increasing the number of mature oocytes available for freezing or fertilization. SN - 1933-7205 UR - https://www.unboundmedicine.com/medline/citation/32617879/Added_Benefit_of_Immature_Oocyte_Maturation_for_Fertility_Preservation_in_Women_with_Malignancy L2 - https://journals.sagepub.com/doi/10.1007/s43032-020-00245-z?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub=pubmed DB - PRIME DP - Unbound Medicine ER -
Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.